Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 19/20 | 0.60 |
| ▸ | NPY1R | P25929 | 11/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.60 |
| ▸ | NPY2R | P49146 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558177 | 0.91 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31265336 | 0.86 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30820031 | 0.86 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29575231 | 0.86 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29700033 | 0.85 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30198871 | 0.85 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30345254 | 0.84 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31620939 | 0.84 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29637822 | 0.84 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30420887 | 0.83 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MMP3, MMP10, MMP25 | NPY4R 4781/4885NPY1R 4585/4885NPY5R 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.